PHIO PHARMACEUTICALS CORP
PHIONASDAQTrading Snapshot
- Day Range
- $478.99 – $490.69
- 52-Week Range
- $0.81 – $4.19
- Volume
- $2.48B
- Avg Volume
- $2.89B
- Shares Outstanding
- 11.6M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $605,138
- P/E Ratio
- -0.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.11
- Dividend Yield
- 0.00%
Why Investors Own PHIO
- ✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PHIO PHARMACEUTICALS CORP
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio
Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision
The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio's global intellectual property portfolio in the United States,